மீரா யாதவ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மீரா யாதவ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மீரா யாதவ் Today - Breaking & Trending Today

Plea for TB drug generic production in India


Plea for TB drug generic production in India
The use of bedaquiline and delamanid has been recommended but, the petitioners have said, the limited supplies make them unavailable to patients
Bombay High Court on Wednesday directed the Centre to respond to a petition seeking legal steps to allow generic production of two patented anti-tuberculosis drugs currently unavailable to all patients in India who need them.
The court has asked the Centre to respond by April 28 to the petition by two TB survivors seeking a government use authorisation order or compulsory licence provisions in Indian patent laws to allow local production of the drugs bedaquiline and delamanid. ....

United Kingdom , Brinelle Dsouza , Anand Grover , Meera Yadav , Jan Swasthya Abhiyan , Leena Menghaney , Bombay High Court On , Janssen Pharmaceuticals , Japan Otsuka Pharmaceuticals , World Trade Organisation , World Health Organisation , Bombay High Court , Otsuka Pharmaceuticals , Lawyers Collective , Brinelled Souza , Medicins Sans Frontieres , ஒன்றுபட்டது கிஂக்டம் , ஆனந்த் தோப்பு , மீரா யாதவ் , ஜான் ஸ்வஸ்தயா அபியன் , குண்டு உயர் நீதிமன்றம் ஆன் , ஜான்சன் மருந்துகள் , ஜப்பான் ஓத்சுக் மருந்துகள் , உலகம் வர்த்தகம் ஆர்கநைஸேஶந் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , குண்டு உயர் நீதிமன்றம் ,

Bombay HC gives time to Centre till April 28 to decide on granting compulsory license to two patented anti-TB drugs | India News


MUMBAI: Bombay high court on Wednesday asked the Centre to decide by April 28 on a representation made last November for ‘compulsory licenses’ to import two patented life-saving anti-TB drugs Bedaquiline and Delamanid.
The compulsory license would to ensure swifter and affordable access to the fairly new drugs that treat multi-drug resistant tuberculosis (MDR-TB) and extensively drug resistant (XDR) cases, said a Public interest litigation (PIL).
“Non-accessibility constitutes a violation of right to life,’’ said senior counsel Anand Grover with advocate Rahul Kamerkar appearing for an NGO, Jan swasthya abhiyan and Thane resident Meera Yadav survivor of XDR-TB who filed the PIL. ....

Justice Dipankar Datta , Rahul Karmerkar , Anil Singh , Anand Grover , Meera Yadav , Jan Swasthya Abhiyan , Justice Girish Kulkarni , Chief Justice Dipankar Datta , Justice Girish , Jan Swasthya , Rifampicin Resistant , Additional Solicitor General Anil Singh , India News , India News Today , Today News , Google News , Breaking News , Tb Persons , Dipankar Datta , நீதி டிபங்கர் தத்தா , அனில் சிங் , ஆனந்த் தோப்பு , மீரா யாதவ் , ஜான் ஸ்வஸ்தயா அபியன் , நீதி கிரீஷ் குல்கர்னி , தலைமை நீதி டிபங்கர் தத்தா ,